Last week, Readycell participated in the annual meeting of the BioprintIA project consortium in front of the CDTI (Centro para el Desarrollo Tecnológico y la Innovación) project officer at Parc Científic of Barcelona.
About the project
BioprintIA is a consortium of six Spanish companies and two technological centers that collaborate across disciplines to conduct industrial research on novel treatments for osteoarticular injuries. Its goal is to create advanced treatments using 3D bioprinting and artificial intelligence (AI) to develop personalized, functionalized, and cellularized bioinks for implants designed to treat osteoarticular injuries.
The event united all the participating companies and partners, who presented the 2023 achievements and the challenges they faced to the project manager. Each presentation showcased the remarkable progress and collaboration, underscoring our shared dedication to innovation and problem-solving.
One of the meeting’s highlights was the visit to Vall d’Hebron Research Institute (VHIR) facilities, where all partners had the opportunity to witness cutting-edge technology firsthand. The team was also able to observe the impressive 3D bioprinter for bioinks, which is pivotal for advancing tissue engineering and animal facilities, gaining insights into the practical applications of our research.
ReadyCell’s contributions
Marta Ollé, principal investigator of the ReadyCell project, presented an organ-on-a-chip prototype in a microfluidic plate format. This technology, which mimics human organ functions on a small scale, can potentially transform drug safety testing and disease modeling, serving as crucial preclinical in vitro systems for evaluating bio-inks and their components.
The encouraging feedback from our peers and the project officer reaffirmed the significant impact of our project and the bright future of our collaborative efforts.
